ADC Therapeutics Posts Narrower Loss In Q4
(RTTNews) - ADC Therapeutics SA (ADCT) reported a net loss for the quarter ended December 31, 2025, of $6.4 million, or a net loss of $0.04 per share, as compared to net loss of $30.7 million, or a net loss of $0.29 per share, prior year. Adjusted net loss was $13.5 million, or an adjusted net loss of $0.09 per share as compared to an adjusted net loss of $26.5 million, or $0.25 share, a year ago.
Net product revenues were $22.3 million for the fourth quarter as compared to $16.4 million for the same period in 2024.
In pre-market trading on NYSE, ADC shares are up 7.58 percent to $4.54.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.